Treatment outcomes in patients receiving conventional amphotericin B therapy: A prospective multicentre study in Taiwan

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 6, 2006, Pages 1181-1188

  Chen, Chien Yuan ^a   Kumar, Ritesh N ^b   Feng, Yin Hsun ^c   Ho, Chao Hung ^d   You, Jie Yu ^d   Liao, Chi Chou ^e   Tseng, Chiung Hui ^e   Mavros, Panagiotis ^b   Gerth, William C ^b   Chen, Yee Chun ^a,f  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b MERCK RESEARCH LABORATORIES   (United States)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Adverse effects; Invasive fungal infections; Length of stay; Medical resources; Mortality; Nephrotoxicity

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; CREATININE; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; POLYPEPTIDE ANTIBIOTIC AGENT;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRYPTOCOCCOSIS; DRUG FATALITY; DRUG MEGADOSE; FEMALE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MYCOSIS; NEPHROTOXICITY; OBSERVATIONAL STUDY; PREDICTION; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TAIWAN; TREATMENT OUTCOME; BLOOD; DRUG EFFECT; KIDNEY; MIDDLE AGED;

ADULT; AGED; AMPHOTERICIN B; CREATININE; FEMALE; HUMANS; KIDNEY; LENGTH OF STAY; MALE; MIDDLE AGED; MYCOSES; PROSPECTIVE STUDIES; TAIWAN; TREATMENT OUTCOME;

EID: 33749186943     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl107     Document Type: Article

References (53)

1. Chen YC, Chang SC, Sun CC et al. Secular trends in the epidemiology of nosocomial fungal infections at a teaching hospital in Taiwan, 1981 to 1993. Infect Control Hosp Epidemiol 1997; 18: 369-75.
2. Hung CC, Chen YC, Chang SC et al. Nosocomial candidemia in a university hospital in Taiwan. J Formos Med Assoc 1996; 95: 19-28.
3. Chen YC, Lin SF, Liu CJ et al. Risk factors for ICU mortality in critically ill patients. J Formos Med Assoc 2001; 100: 656-61.
4. Chen YC, Chang SC, Shin CC et al. Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan. Diagn Microbiol Infect Dis 2000; 36: 175-83.
5. Shin CC, Chen YC, Chang SC et al. Cryptococcal meningitis in non-HIV infected patients. QJM 2000; 93: 245-51.
6. Jean SS, Gang CT, Shau WY et al. Cryptococcemia: Clinical features and prognostic factors. Q J Med 2002; 95: 1-8.
7. Lai HP, Chen YC, Chang LY et al. Invasive fungal infection in children with persistent febrile neutropenia. J Formos Med Assoc 2005; 104: 174-9.
8. Chen CY, Chen YC, Tang JL et al. Hepatosplenic fungal infection in patients with acute leukemia in Taiwan: Incidence, treatment and prognosis. Ann Hematol 2003; 82: 1-9.
9. Patterson TF, Kirkpatrick WR, White M et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 2000; 79: 250-60.
10. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
11. Ostrosky-Zeichner L, Marr KA, Rex JH et al. Amphotericin B: Time for a new 'gold standard'. Clin Infect Dis 2003; 37: 415-25.
12. Rex JH, Walsh TJ. Estimating the true cost of amphotericin B. Clin Infect Dis 1999; 29: 1408-10.
13. McCurdy DK, Frederic M, Elkinton JR. Renal tubular acidosis due to amphotericin B. N Engl J Med 1968; 278:124-30.
14. Lin AC, Goldwasser E, Bernard EM et al. Amphotericin B blunts erythropoietin response to anemia. J Infect Dis 1990: 161: 348-51.
15. Girois SB, Chapuis F, Decullier E et al. Adverse effects of antifungal therapies in invasive fungal infections: Review and meta-analysis. Eur J Clin Microbiol Infect Dis 2005; 24: 119-30.
16. Costa S, Nucci M. Can we decrease amphotericin nephrotoxicity? Curr Opin Crit Care 2001; 7: 379-83.
17. Classen DC, Pestotnik SIL, Evans RS et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277: 301-6.
18. Bates DW. Spell N, Cullen DJ et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997; 277: 307-11.
19. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromsed patients with cancer and hematopoietic stem cell transplant: An international consensus. Clin Infect Dis 2002: 34: 7-14.
20. Harbarth S, Pestotnik LS, LIoyd JF et al. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001; 111: 528-34.
21. Harbarth S, Burke JP, Lloyd JF et al. Clinical and economic outcomes of conventional amphotericin B associated nephropathy. Clin Infect Dis 2002; 35: 120-7.
22. Bates DW, Su L, Yu DT et al. Mortality and cost of acute renal failure associated with amphatericin B therapy. Clin infect Dis 2001; 32: 686-93.
23. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 187-220.
24. Kalbfleisch JD, Prentice RL eds. The Statistical Analysis of Failure Time Data, Wiley Series in Probability and Mathematical Statistics. New York, USA: John Wiley & Sons Inc., 1980.
25. Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin infect Dis 1999; 29: 1402-7.
26. Luber AD, Maa L, Lam M et al. Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 1999; 43: 267-71.
27. Leenders AC, Daenen S, Jansen RL et al. Liposomal amphoterin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998; 103: 205-12.
28. Prentice HG, Hann LM, Herbrecht R et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711-8.
29. White MH, Bowden RA, Sandler E et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27: 296-302.
30. Walsh TJ, Finberg RW, Amdt C et al. Liposomai amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Disease Mycoses Study Group. N Engl J Med 1999; 340: 764-71.
31. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
32. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
33. Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: A randomised non-inferiority trial. Lancet2005; 366: 1435-42.
34. Girmenia C, Gentile G, Micozzi A et al. Nephrotoxicity of amphotericin B desoxycholate. Clin Infect Dis 2001; 33: 915-6.
35. Girmenia C, Cimino G, Micozzi A et al. Risk factors for nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2002; 113: 351.
36. Marr KA. Empirical antifungal therapy - new options, new tradeoffs. N Engl J Med 2002; 346: 278-80.
37. Klastersky J. Antifungal therapy in patients with fever and neutropenia - more rational and less empirical? N Engl J Med 2004; 351: 1445-7.
38. Sheng WH, Wang JT, Lu DCT et al. Comparative impact of hospital-acquired infections on medical costs, length of hospital stay and outcome between community hospitals and medical centers. J Hosp Infection 2005; 59: 205-14.
39. Gubbins PO, Penzak SR, Polston S et al. Characterizing and predicting amphotericin B-associated nephrotoxcity in bone marrow or peripheral blood stem cell transplant recipients. Pharmacotherapy 2002; 22: 961-71.
40. Wingard JR, Leather H. A new era of antifungal therapy. Biol Blood Marrow Transplant 2004; 10: 73-90.
41. Walsh TJ, Teppler H, Donowtz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
42. Cheng SH, Chiang TL. The effect of universal health insurance on health care utilization in Taiwan. Results from a natural experiment. JAMA 1997; 278: 89-93.
43. Llanos A, Cieza J, Bernardo J et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991; 40: 302-8.
44. Anderson CM. Sodium chloride treatment of amphotericin B nephrotoxicity. Standard of care? West J Med 1995; 162: 313-7.
45. Mayer J, Doubek M, Doubek J et al. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: Animal experiments and clinical study. J Infect Dis 2002; 186: 379-88.
46. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: Randomised controlled trial. BMJ 2001; 322: 579-82.
47. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: An open-label observational study. Clin Infect Dis 2003; 36: 943-51.
48. Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89.
49. Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 710-8.
50. Chen YC, Chang SC, Luh KT et al. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother 2003; 52: 71-7.
51. Wang JL, Chang SC, Hsueh PR et al. Species distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002. J Microbiol Immunol Infect 2004; 37: 236-41.
52. Bachmann SP, VandeWalle K, Ramage G et al. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrobial Agents Chemother 2002; 46: 3591-6.
53. Bohme A, Ruhnke M, Buchheidt D et al. Treatment of fungal infections in hematology and oncology - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82 Suppl 2: S133-40.